Results 91 to 100 of about 1,367 (120)

Efficacy and Safety of Voretigene Neparvovec in <i>RPE65</i>-Retinopathy: Results of a Phase III Trial in Japan. [PDF]

Ophthalmol Sci
Fujinami K, Akiyama K, Tsunoda K, Ito S, Seko N, Yamamoto S.   +5 more
europepmc   +1 more source

Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec. [PDF]

JAMA Ophthalmol, 2020
Levi SR, Oh JK, de Carvalho JRL, Mahajan VB, Tsang SH, Sparrow JR.   +5 more
europepmc   +1 more source

Voretigene Neparvovec and Gene Therapy for Leber's Congenital Amaurosis: Review of Evidence to Date. [PDF]

Appl Clin Genet, 2020
Padhy SK, Takkar B, Narayanan R, Venkatesh P, Jalali S.   +4 more
europepmc   +1 more source

Real-world outcomes of Voretigene Neparvovec: a single-centre consecutive case series. [PDF]

Eye (Lond)
Jalil A, Ferrara M, Lippera M, Parry N, Black GC, Banderas S, Ashworth J, Biswas S, Hall G, Gray J, Newman W, Ivanova T.   +11 more
europepmc   +1 more source

Chorioretinal Atrophy Growth After Voretigene Neparvovec Retinotopically Is Connected to Retinal Functional Rescue. [PDF]

Transl Vis Sci Technol
Stingl K, Kempf M, Jung R, Stingl K.
europepmc   +1 more source

Cost Effectiveness of Voretigene Neparvovec for RPE65-Mediated Inherited Retinal Degeneration in Germany. [PDF]

Transl Vis Sci Technol, 2020
Uhrmann MF, Lorenz B, Gissel C.
europepmc   +1 more source

An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK. [PDF]

Adv Ther, 2020
Viriato D, Bennett N, Sidhu R, Hancock E, Lomax H, Trueman D, MacLaren RE.   +6 more
europepmc   +1 more source

Chorioretinal Atrophy after Voretigene Neparvovec Therapy in <italic>RPE65</italic> Mutation-Associated Inherited Retinal Disease: Longitudinal Characterization in Multimodal Imaging.

Ophthalmologica
Sassen SH, Sassmannshausen M, Sassen J, Preising MN, Scholz JP, Holz FG, Lorenz B, Herrmann P.   +7 more
europepmc   +1 more source

ICER reviewing voretigene neparvovec

, 2017

core   +1 more source

Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease.

JAMA Ophthalmol, 2019
Johnson S, Buessing M, O'Connell T, Pitluck S, Ciulla TA.   +4 more
europepmc   +1 more source